The DOI matches its Crossref record.
Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
Open accessAbstract
ObjectiveTo analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR). MethodsThis retrospective cohort study was based on the registry of the German Neuromyelitis Optica Study Group, a nationwide network established in 2008. It recruited patients with neuromyelitis optica diagnosed according to the 2006 Wingerchuk criteria or with aquaporin-4 (AQP4-ab)-antibody–seropositive NMOSD treated at 6 regional hospitals and 16 tertiary referral centers until March 2013. Besides descriptive data analysis of patient and attack characteristics, generalized estimation equation (GEE) analyses were applied to compare the effectiveness of the 2 apheresis techniques. A GEE model was generated to assess predictors of outcome. ResultsTwo hundred and seven attacks in 105 patients (87% AQP4-ab-antibody seropositive) were treated with at least 1 apheresis therapy. Neither PE nor IA was proven superior in the therapy of NMOSD attacks. CR was only achieved with early apheresis therapy. Strong predictors for CR were the use of apheresis therapy as first-line therapy (OR 12.27, 95% CI: 1.04–144.91, p = 0.047), time from onset of attack to start of therapy in days (OR 0.94, 95% CI: 0.89–0.99, p = 0.014), the presence of AQP4-ab-antibodies (OR 33.34, 95% CI: 1.76–631.17, p = 0.019), and monofocal attack manifestation (OR 4.71, 95% CI: 1.03–21.62, p = 0.046). ConclusionsOur findings suggest early use of an apheresis therapy in NMOSD attacks, particularly in AQP4-ab-seropositive patients. No superiority was shown for one of the 2 apheresis techniques. Classification of evidenceThis study provides Class IV evidence that for patients with NMOSD, neither PE nor IA is superior in the treatment of attacks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Self-citationNeuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Carnero Contentti, E., & Correale, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 338
Diagnosis and classification of optic neuritis
Petzold, A., Fraser, C. L., Abegg, M., Alroughani, R., Alshowaeir, D., Alvarenga, R., Andris, C., Asgari, N., Barnett, Y., Battistella, R., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00200-9 · Cited by 330
Self-citation
Metadata
- Authors
- Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K.-D., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., Kümpfel, T., Aktas, O., Hartung, H.-P., Ringelstein, M., Geis, C., Kleinschnitz, C., Berthele, A., Hemmer, B., Angstwurm, K., Stellmann, J.-P., Schuster, S., Stangel, M., Lauda, F., Tumani, H., Mayer, C., Krumbholz, M., Zeltner, L., Ziemann, U., Linker, R., Schwab, M., Marziniak, M., Then Bergh, F., Hofstadt-van Oy, U., Neuhaus, O., Zettl, U. K., Faiss, J., Wildemann, B., Paul, F., Jarius, S., Trebst, C., on behalf of NEMOS (Neuromyelitis Optica Study Group), on behalf of NEMOS (Neuromyelitis Optica Study Group), Albrecht, P., Ayzenberg, I., Bayas, A., Bellmann-Strobl, J., Bischof, F., Bittner, S., Böttcher, T., Brettschneider, J., Buttmann, M., DSouza, M., Ettrich, B., Frank, B., Gass, A., Grothe, M., Guthke, K., Haarmann, A., Habedank, E., Hoffmann, F., Hoffmann, O., Hümmert, M. W., Junghans, J., Kaste, M., Kaulen, B., Kermer, P., Kern, P., Klotz, L., Köhler, W., Kolesilova, E., Korsen, M., Kowarik, M., Langel, S., Lee, D. H., Liebetrau, M., Luessi, F., Marouf, W., Meister, S., Melms, A., Metz, I., Münch, C., Niehaus, S., Pawlitzki, M., Pellkofer, H., Puhlmann, H. U., Pul, R., Retzlaf, N., Riedlinger, A., Rommer, P., Röpke, L., Rostásy, K., Rückriem, L., Ruschil, C., Schippling, S., Senel, M., Sieb, J. P., Sommer, C., Spreer, A., Steinbrecher, A., Stephanik, H., Stoppe, M., Süße, M., Tackenberg, B., Tünnerhoff, J., Veauthier, C., Walter, A., Wandinger, K. P., Warnke, C., Weber, M. S., Weissert, R., Wiendl, H., Wilke, C., Winkelmann, A., Yalachkov, Y., Young, K., Zentner, C., & Zipp, F.
- Venue
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2018-11
- Volume
- 5
- Issue
- 6
- Pages
- e504-e504
- ISSN
- 2332-7812 (ISSN-L)
- OpenAlex
- W2893913323
- Cited by
- 240
- References
- 0
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. https://app.cochat.ai/papers/10.1212/nxi.0000000000000504
- The paper
- Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K.-D., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., Kümpfel, T., Aktas, O., Hartung, H.-P., Ringelstein, M., Geis, C., Kleinschnitz, C., Berthele, A., Hemmer, B., Angstwurm, K., Stellmann, J.-P., . . . Zipp, F. (2018). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000000504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.